Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants

Cytotherapy. 2017 Jan;19(1):36-46. doi: 10.1016/j.jcyt.2016.10.006. Epub 2016 Nov 14.

Abstract

Background aims: Extensive animal data indicate that mesenchymal stromal cells (MSCs) improve outcome in stroke models. Intra-arterial (IA) injection is a promising route of delivery for MSCs. Therapeutic effect of MSCs in stroke is likely based on the broad repertoire of secreted trophic and immunomodulatory cytokines produced by MSCs. We determined the differential effects of exposing MSCs to different types of clinically relevant vehicles, and/or different additives and passage through a catheter relevant to IA injections.

Methods: MSCs derived from human bone marrow were tested in the following vehicles: 5% albumin (ALB), 6% Hextend (HEX) and 40% dextran (DEX). Each solution was tested (i) alone, (ii) with low-dose heparin, (iii) with 10% Omnipaque, or (iv) a combination of heparin and Omnipaque. Cells in vehicles were collected directly or passed through an IA catheter, and MSC viability and cytokine release profiles were assessed.

Results: Cell viability remained above 90% under all tested conditions with albumin being the highest at 97%. Viability was slightly reduced after catheter passage or exposure to heparin or Omnipaque. Catheter passage had little effect on MSC cytokine secretion. ALB led to increased release of angiogenic factors such as vascular endothelial growth factor compared with other vehicles, while HEX and DEX led to suppression of pro-inflammatory cytokines such as interleukin-6. However, when these three vehicles were subjected to catheter passage and/or exposure to additives, the cytokine release profile varied depending on the combination of conditions to which MSCs were exposed.

Discussion: Exposure of MSCs to certain types of vehicles or additives changes the profile of cytokine secretion. The activation phenotype of MSCs may therefore be affected by the vehicles used for these cells or the exposure to the adjuvants used in their administration.

Keywords: cytokines; delivery; mesenchymal stromal cell (MSC); secretome.

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Bone Marrow Cells / cytology
  • Cell Survival
  • Cytokines / metabolism
  • Heparin / pharmacology
  • Humans
  • Interleukin-6 / metabolism
  • Iohexol / pharmacology
  • Mesenchymal Stem Cell Transplantation / instrumentation
  • Mesenchymal Stem Cell Transplantation / methods*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / metabolism*
  • Suspensions
  • Time Factors
  • Vascular Access Devices*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Adjuvants, Immunologic
  • Cytokines
  • IL6 protein, human
  • Interleukin-6
  • Suspensions
  • Vascular Endothelial Growth Factor A
  • Iohexol
  • Heparin